Paper36036883
HDAC6: A unique HDAC family member as a cancer target.
Kaur S and 2 others. Cell Oncol (Dordr), 2022. Cited by 76 papers, by iCite.
Cite this record
ConductScience Library. HDAC6: A unique HDAC family member as a cancer target. Papers, record 36036883. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36036883
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Neoplasms | Major topic |
| Animals | |
| Mice | |
| Histone Deacetylase 6 | |
| Histone Deacetylase Inhibitors | |
| Proteasome Inhibitors |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 19/06/2016(I)EU-V | University Grants Commission | PubMed | ||
| DBT/2021-22/CBR/1593 | Department of Biotechnology, Government of India | PubMed |
Source PubMed
References234
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35223194 | Coupling the immunomodulatory properties of the HDAC6 inhibitor ACY241 with Oxaliplatin promotes robust anti-tumor response in non-small cell lung cancer. | Oncoimmunology | 2022 | https://conductscience.org/library/papers/35223194 | PubMed |
| 2 | 16192271 | HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin. | J Biol Chem | 2005 | https://conductscience.org/library/papers/16192271 | PubMed |
| 3 | 26824318 | MIIP accelerates epidermal growth factor receptor protein turnover and attenuates proliferation in non-small cell lung cancer. | Oncotarget | 2016 | https://conductscience.org/library/papers/26824318 | PubMed |
| 4 | 15937340 | Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. | J Biol Chem | 2005 | https://conductscience.org/library/papers/15937340 | PubMed |
| 5 | 18804549 | Acetylation of non-histone proteins modulates cellular signalling at multiple levels. | Int J Biochem Cell Biol | 2009 | https://conductscience.org/library/papers/18804549 | PubMed |
| 6 | 17785525 | HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates. | Genes Dev | 2007 | https://conductscience.org/library/papers/17785525 | PubMed |
| 7 | 23627282 | Development and therapeutic implications of selective histone deacetylase 6 inhibitors. | J Med Chem | 2013 | https://conductscience.org/library/papers/23627282 | PubMed |
| 8 | 29917295 | A452, an HDAC6-selective inhibitor, synergistically enhances the anticancer activity of chemotherapeutic agents in colorectal cancer cells. | Mol Carcinog | 2018 | https://conductscience.org/library/papers/29917295 | PubMed |
| 9 | 29278704 | HDAC6 interacts with PTPN1 to enhance melanoma cells progression. | Biochem Biophys Res Commun | 2018 | https://conductscience.org/library/papers/29278704 | PubMed |
| 10 | 30667160 | Combined comparative molecular field analysis, comparative molecular similarity indices analysis, molecular docking and molecular dynamics studies of histone deacetylase 6 inhibitors. | Chem Biol Drug Des | 2019 | https://conductscience.org/library/papers/30667160 | PubMed |
| 11 | 20008322 | IIp45 inhibits cell migration through inhibition of HDAC6. | J Biol Chem | 2010 | https://conductscience.org/library/papers/20008322 | PubMed |
| 12 | 33024443 | Synergistic Enhancement of Cancer Therapy Using HDAC Inhibitors: Opportunity for Clinical Trials. | Front Genet | 2020 | https://conductscience.org/library/papers/33024443 | PubMed |
| 13 | 23950178 | PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. | Blood | 2013 | https://conductscience.org/library/papers/23950178 | PubMed |
| 14 | 6863393 | Chlamydomonas alpha-tubulin is posttranslationally modified in the flagella during flagellar assembly. | J Cell Biol | 1983 | https://conductscience.org/library/papers/6863393 | PubMed |
| 15 | 30867374 | Novel HDAC6 selective inhibitors with 4-aminopiperidine-1- carboxamide as the core structure enhanced growth inhibitory activity of bortezomib in MCF-7 cells. | Biosci Trends | 2019 | https://conductscience.org/library/papers/30867374 | PubMed |
| 16 | 29880608 | In vitro and in vivo activity of a new small-molecule inhibitor of HDAC6 in mantle cell lymphoma. | Haematologica | 2018 | https://conductscience.org/library/papers/29880608 | PubMed |
| 17 | 22936009 | The role of HDAC6 in Alzheimer's disease. | J Alzheimers Dis | 2013 | https://conductscience.org/library/papers/22936009 | PubMed |
| 18 | 12486003 | In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation. | EMBO J | 2002 | https://conductscience.org/library/papers/12486003 | PubMed |
| 19 | 23905680 | Quinazolin-4-one derivatives as selective histone deacetylase-6 inhibitors for the treatment of Alzheimer's disease. | J Med Chem | 2013 | https://conductscience.org/library/papers/23905680 | PubMed |
| 20 | 27400681 | GFRα2 prompts cell growth and chemoresistance through down-regulating tumor suppressor gene PTEN via Mir-17-5p in pancreatic cancer. | Cancer Lett | 2016 | https://conductscience.org/library/papers/27400681 | PubMed |
Cited by37
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 76 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42661166 | Exploration of novel hydroxamic acid-based candidates integrating chalcone scaffold cap as multitarget HDAC inhibitors: design, anti-prostatic cancer assessment, in silico docking and molecular dynamic simulation. | J Enzyme Inhib Med Chem | 2026 | https://conductscience.org/library/papers/42661166 | PubMed |
| 42176187 | An integrated machine learning and chemical space network approach for the design of potent epigenetic HDAC6 inhibitors for targeting neurological disorders. | Mol Divers | 2026 | https://conductscience.org/library/papers/42176187 | PubMed |
| 42063468 | Therapeutic potential of HDAC6 inhibitor Tubastatin A in health and diseases: current perspective and future directions. | Mil Med Res | 2026 | https://conductscience.org/library/papers/42063468 | PubMed |
| 41999432 | Aucubin inhibits epithelial-mesenchymal transition and angiogenesis in colorectal cancer via the HDAC6/PI3K/Akt signaling pathway. | Naunyn Schmiedebergs Arch Pharmacol | 2026 | https://conductscience.org/library/papers/41999432 | PubMed |
| 41850897 | Investigation of Novel Antiproliferative Drugs Interaction with mPEG2k-PCLy Copolymers Using Molecular Dynamics Simulation Approach. | J Chem Inf Model | 2026 | https://conductscience.org/library/papers/41850897 | PubMed |
| 41501879 | HDAC6 orchestrates metastatic and immunosuppressive programs in small cell lung cancer through S100A2-TGF-β/SMAD and CSF1R signaling. | Mol Cancer | 2026 | https://conductscience.org/library/papers/41501879 | PubMed |
| 41498889 | Role of HDAC6 in carcinomas. | Discov Oncol | 2026 | https://conductscience.org/library/papers/41498889 | PubMed |
| 41335282 | Epigenetic drugs in cancer therapy: mechanisms, immune modulation, and therapeutic applications. | Mol Biomed | 2025 | https://conductscience.org/library/papers/41335282 | PubMed |
| 41082153 | Identifying the causal role and therapeutic potential of immune-related genes in bladder cancer: a Mendelian randomization study. | Discov Oncol | 2025 | https://conductscience.org/library/papers/41082153 | PubMed |
| 40641131 | Histone deacetylase 6: A new player in oxidative stress‑associated disorders and cancers (Review). | Int J Mol Med | 2025 | https://conductscience.org/library/papers/40641131 | PubMed |
| 40542929 | Assessment of test-retest reproducibility by [18F]Bavarostat for PET imaging of HDAC6. | EJNMMI Res | 2025 | https://conductscience.org/library/papers/40542929 | PubMed |
| 40532131 | Development and Characterization of the First Selective Class IIb Histone Deacetylase Degraders. | J Med Chem | 2025 | https://conductscience.org/library/papers/40532131 | PubMed |
| 40167251 | Histone Deacetylase 6 (HDAC6) in Ciliopathies: Emerging Insights and Therapeutic Implications. | Adv Sci (Weinh) | 2025 | https://conductscience.org/library/papers/40167251 | PubMed |
| 39941046 | Regulation of HDAC6 Catalytic Activity in Cancer: The Role of Post-Translational Modifications and Protein-Protein Interactions. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/39941046 | PubMed |
| 39885716 | Pioneering first-in-class HDAC-ROCK inhibitors as potential multitarget anticancer agents. | Future Med Chem | 2025 | https://conductscience.org/library/papers/39885716 | PubMed |
| 39790566 | Histone deacetylase 6 inhibition prevents hypercholesterolemia-induced erectile dysfunction independent of changes in markers of autophagy. | Sex Med | 2024 | https://conductscience.org/library/papers/39790566 | PubMed |
| 39595195 | The Role of HDAC6 in Glioblastoma Multiforme: A New Avenue to Therapeutic Interventions? | Biomedicines | 2024 | https://conductscience.org/library/papers/39595195 | PubMed |
| 39568023 | Adipose stem cell exosomes, stimulated by pro-inflammatory factors, enhance immune evasion in triple-negative breast cancer by modulating the HDAC6/STAT3/PD-L1 pathway through the transporter UCHL1. | Cancer Cell Int | 2024 | https://conductscience.org/library/papers/39568023 | PubMed |
| 39458584 | Development of Novel ROCK Inhibitors via 3D-QSAR and Molecular Docking Studies: A Framework for Multi-Target Drug Design. | Pharmaceutics | 2024 | https://conductscience.org/library/papers/39458584 | PubMed |
| 39433125 | Targeting chaperone modifications: Innovative approaches to cancer treatment. | J Biol Chem | 2024 | https://conductscience.org/library/papers/39433125 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| HDAC6 | 10013 | PubTator's text mining | https://conductscience.org/library/genes/10013 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36036883
GET https://conductscience.org/api/papers/v1/36036883/references?page=2